MedTrace Logo

Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia

NCT01813955 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2015-05-28

No results posted yet for this study

Summary

Phosphodiesterase (PDE) inhibitors represent a new group of potential antipsychotic compounds currently under development. One of these is papaverine, an inhibitor of the PDE 10 family. The class of PDE10 inhibitors have been reported as possible candidates in the treatment of schizophrenia, and may prove an attractive antipsychotic alternative due to the many side-effects of the currently available antipsychotics. It has been proposed from preclinical studies that PDE10 inhibitors have the potential to reduce cognitive deficits in schizophrenia and these findings need to be confirmed in a human population, in view of the fact that no other currently registered drug posses these unique properties.

The currently proposed project is designed to investigate whether the PDE10 inhibitor Papaverine indeed have the capacity to reduce cognitive deficits in schizophrenia patients. In order to accomplish this effect, Papaverine will be investigated in schizophrenia, with regards to symptomatology, hemodynamic, neurocognition and early information-processing.

Conditions

Interventions

DRUG

Papaverine or placebo

Papaverine delayed release (depot capsule, 300 mg, orally, one single dosage per subject) or placebo

Sponsors & Collaborators

  • Glostrup University Hospital, Copenhagen

    collaborator OTHER

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Birte Glenthøj, Professor · University of Copenhagen

  • Mikkel E Sørensen, PHD student · University of Copenhagen

  • Bob Oranje, PHD · Center for Neuropsychiatric Schizophrenia Research

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-05-31
Completion
2013-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01813955 on ClinicalTrials.gov